Werewolf Therapeutics, Inc. (HOWL)
NASDAQ: HOWL · Real-Time Price · USD
0.740
-0.090 (-10.84%)
At close: Apr 28, 2026, 4:00 PM EDT
0.740
0.00 (0.00%)
Pre-market: Apr 29, 2026, 7:03 AM EDT
Werewolf Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
39
Market Cap
35.96M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Atara Biotherapeutics | 120.77M |
| Veru Inc. | 16.89M |
| CervoMed | 4.01M |
| Aligos Therapeutics | 2.19M |
| RenovoRx | 1.12M |
| Actinium Pharmaceuticals | 90.00K |
| INmune Bio | 50.00K |
HOWL News
- 4 weeks ago - Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates - GlobeNewsWire
- 2 months ago - Werewolf Therapeutics Announces Plan to Explore Strategic Alternatives - GlobeNewsWire
- 4 months ago - Werewolf Therapeutics Announces Pipeline and Business Updates - GlobeNewsWire
- 6 months ago - Werewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting - GlobeNewsWire
- 6 months ago - Werewolf Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 7 months ago - Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer - GlobeNewsWire
- 7 months ago - Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting - GlobeNewsWire
- 8 months ago - Werewolf Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference - Transcripts